Amneal ‘Very Excited’ About Biosimilars Future, Looks To Expand Portfolio In 2024

Complex Generics Also Remain Key R&D Focus Area, Particularly Inhalators And Injectables

 
• By Urtė Fultinavičiūtė
  
Businessman surfing financial stock
Amneal said the “next wave of affordable medicines is biosimilars” • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business